Subtle Medical Secures FDA Clearance for AI-Powered SubtleHD CT
MENLO PARK, Calif., June 10, 2026 Subtle Medical has received U.S. FDA clearance for SubtleHD™(CT), a new artificial intelligence-powered...
artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Eli Lilly FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology NSCLC Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
MENLO PARK, Calif., June 10, 2026 Subtle Medical has received U.S. FDA clearance for SubtleHD™(CT), a new artificial intelligence-powered...
MILFORD, Massachusetts, USA – June 3, 2026 Waters Corporation has announced U.S. Food and Drug Administration (FDA) 510(k) clearance...
SAN DIEGO, Calif., June 3, 2026 Zepto Life Technology has achieved a significant regulatory milestone after receiving U.S. Food...
AUSTIN, Texas, May 26, 2026 TOBY, Inc., a biotechnology company focused on non-invasive disease detection technologies, has announced that...
ABBOTT PARK, Ill., May 27, 2026 Abbott has announced that the updated American Cancer Society (ACS) colorectal cancer screening...
BERLIN, Germany / WHIPPANY, N.J., May 7, 2026 Bayer announced positive topline results from the pivotal Phase III REVEAL...
Melbourne, Australia and Indianapolis, IN, United States – May 5, 2026 Telix Pharmaceuticals Limited has announced the publication of...
MILWAUKEE, Feb. 14, 2026 — New research presented at the AAAAI Annual Meeting 2026 demonstrates that machine learning (ML)...
LONDON, UK, Feb. 12, 2026 — Serac Healthcare announced that the U.S. Food and Drug Administration has granted Fast...
BOSTON, January 22, 2026 — Delve Bio announced new clinical evidence demonstrating that earlier use of metagenomic next-generation sequencing...
